In this context, the low molecular weight GA-1 and GA-2 can act as lead compounds in the development of specific small molecule inhibitors of NF-κΒ p65 with significant therapeutic potential for chronic neurodegenerative diseases including AD (Fig 8). The gene discussed is ETFA; the disease is Alzheimer disease.